v3.26.1
Revenue from contract with customer (Details)
€ in Millions, $ in Millions
 1 Months Ended 12 Months Ended 15 Months Ended
Jul. 01, 2023
CHF (SFr)
Nov. 01, 2022
CHF (SFr)
May 01, 2021
CHF (SFr)
Oct. 30, 2020
USD ($)
Jan. 02, 2018
USD ($)
item
Aug. 31, 2022
CHF (SFr)
Jan. 31, 2018
USD ($)
Dec. 31, 2025
CHF (SFr)
Dec. 31, 2024
CHF (SFr)
Jun. 30, 2024
CHF (SFr)
Dec. 31, 2023
CHF (SFr)
Dec. 31, 2019
USD ($)
Jul. 31, 2022
CHF (SFr)
Dec. 31, 2004
EUR (€)
Revenue from contract with customer                            
Revenue from contract with customer               SFr 29,972 SFr 404,102   SFr 1,612,953 [1]      
Indivior PLC                            
Revenue from contract with customer                            
Number of distinct material promises and performance obligations | item         2                  
Indivior PLC | Rights granted                            
Revenue from contract with customer                            
Revenue from contract with customer | $             $ 5.0              
Indivior PLC | Achievement of pre-specified milestones                            
Revenue from contract with customer                            
Variable consideration allocated to contract | $         $ 330.0                  
Indivior PLC | Research                            
Revenue from contract with customer                            
Revenue from contract with customer                 300,000   1,600,000      
Initial research term         2 years                  
Contract funding for research and development costs incurred | $         $ 4.0                  
Increment period for extension of research term         12 months                  
Number of newly identified compounds selected | item         1                  
Additional funding for research and development costs incurred SFr 2,700,000 SFr 950,000 SFr 3,700,000 $ 2.8   SFr 850,000           $ 1.6    
Research funding received                   SFr 1,100,000     SFr 2,700,000  
Research funding paid by investor to third parties                   SFr 1,600,000     SFr 1,000,000  
Trade receivable               0 100,000          
Indivior PLC | Research | Indivior PLC                            
Revenue from contract with customer                            
Number of newly identified compounds selected | item         1                  
Indivior PLC | Maintenance of patents                            
Revenue from contract with customer                            
Revenue from contract with customer               29,972 94,127   40,891      
Janssen Pharmaceuticals Inc. | Development                            
Revenue from contract with customer                            
Revenue from contract with customer               SFr 0 SFr 0   SFr 0      
Janssen Pharmaceuticals Inc. | Development | Maximum                            
Revenue from contract with customer                            
Variable consideration allocated to contract | €                           € 109
[1] The comparative information has been re-presented due to discontinued operations that have been reclassed to the financial line called “Net profit or loss from discontinued operations” (note 23). In the other sections of these consolidated financial statements an asterisk will indicate where comparative information has been re-presented